-

AHF: Global HIV Response Demands Broader Lenacapavir Access

LOS ANGELES--(BUSINESS WIRE)--While AIDS Healthcare Foundation (AHF) welcomed news of Gilead’s expansion of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic manufacturers, key HIV-affected countries excluded from the deal—particularly those in Latin America and others—must also have affordable access to this breakthrough treatment, irrespective of their World Bank income classification.

“This license excludes 2 million people living with HIV in Latin America — notably in Brazil, Mexico, Argentina, Colombia, and Peru. It excludes them because Gilead sees the Latin American market as a place where it can profit off the backs of sick people. Generic access to lenacapavir is a step in the right direction, especially for improving treatment adherence, but a drug with this much promise to save countless lives must be affordable to all nations that need it,” said AHF President Michael Weinstein.

“And while generic manufacturers in India, Pakistan, Egypt, and the U.S. have been granted licenses,” added Weinstein, “South Africa has a robust pharmaceutical sector and should have been included in the deal to address its own enormous HIV burden and help support the response across the rest of the continent at a reduced cost.”

Further concerns remain around pricing transparency as Gilead and the licensees are yet to clarify how lenacapavir will be priced in the included countries. AHF strongly believes lenacapavir must be made accessible to all countries at an affordable price that reflects the realities on the ground and is in line with the global HIV/AIDS targets.

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 2 million people in 48 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1 323.308.1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Senior Director of Media Relations, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

AIDS Healthcare Foundation


Release Versions

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1 323.308.1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Senior Director of Media Relations, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

More News From AIDS Healthcare Foundation

Bloom: Celebrating AHF’s Activism Through Augmented Reality and Art

LOS ANGELES--(BUSINESS WIRE)--Bloom: Celebrating AHF’s Activism Through Augmented Reality and Art--2 Night Only Art Exhibition in Hollywood, January 20 and 21...

New Study Shows How Florida Can Strengthen Public Trust and Cooperation in Future Pandemics

MIAMI--(BUSINESS WIRE)--A new study from the University of Miami Public Health Policy Lab and the AHF Global Public Health Institute sheds light on why public trust broke down during the COVID-19 pandemic—and what can be done to rebuild it before the next health emergency. Drawing on interviews with government, academic, and private-sector leaders across Florida, the study found that distrust in public health grew due to a lack of transparency, political tensions, and inconsistent communication...

New Billboards Mark AHF’s 50 Country Milestone, Promote Easy Testing

LOS ANGELES--(BUSINESS WIRE)--New Billboards Mark AHF’s 50 Country Milestone, Promote Ease of Testing...
Back to Newsroom